Lawrence Shombert, MD
Radiation Oncology · Cumberland, MDNPI 1679555452
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,363 of the $9,385 with a category attached, or 67.8%. 50 manufacturers reported payments, led by AstraZeneca at 41.2% of the total. Among radiation oncology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $53.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Johnson & Johnson$535
- Incyte Corporation$406
- Merck$393
- Eisai Inc.$318
- Genentech USA, Inc.$296
- plus $4K from 44 others
What the payments were for
- Consulting fees$2,94031%
- Speaking & faculty fees$250%
- Food & beverage$6,36368%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,385 in reported general payments places this provider in the 90th percentile of 108 radiation oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 68 | $429 |
| Lidocaine Hcl ViscousLidocaine Hcl | 13 | $255 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Cumberland
- Sahaja AcharyaBaltimore$200K
- Arpit ChhabraBaltimore$97K
- Robert BrooklandTowson$34K
- Lawrence KleinbergBaltimore$34K
- Danny SongBaltimore$32K
- Jason MolitorisBaltimore$26K
- Kristin RedmondBaltimore$17K
- John MansuetiBerlin$11K
- Avani RaoBaltimore$10K
- Amanda WalkerBaltimore$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.